1 / 27

ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.

ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta. En el año 2009…. Clase funcional II-III NYHA FE ≤ 30% QRS ≥ 120 msec o QRS estimulado ≥ 200 msec. DAI convencional o DAI Resincronizador Objetivo principal: Hospitalización o muerte de cualquier causa. Clase II NYHA 80% FA 12,7%

lamont
Télécharger la présentation

ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARRITMIAS Ignacio Fernández Lozano.Javier Alzueta.

  2. En el año 2009…..

  3. Clase funcional II-III NYHA • FE ≤ 30% • QRS ≥ 120 msec o QRS estimulado ≥ 200 msec. • DAI convencional o DAI Resincronizador • Objetivo principal: Hospitalización o muerte de cualquier causa.

  4. Clase II NYHA 80% FA 12,7% QRS medio 157 msec. BRI 72% MP 7,5%

  5. QRS > 150 msec FE < 20% BRI

  6. Criterios de inclusión del MADIT-II IM con onda Q > 4 semanas FEVI < 0.30 > 21 años de edad; sin límite superior de edad No se requiere TVNS ni EEF Moss AJ. N Engl J Med. 2002;346:877-83.

  7. MADIT-II: Resultados de supervivencia 1.0 0.9 Desfibrilador 0.8 Probabilidad de supervivencia 0.7 Convencional P = 0,007 0.6 0.0 0 1 2 3 4 Año N.° en riesgo Desfibrilador 742 502 (0,91) 274 (0,94) 110 (0,78) 9 Convencional 490 329 (0,90) 170 (0,78) 65 (0,69) 3 Moss AJ. N Engl J Med. 2002;346:877-83.

  8. Mortalidad total No DAI 62% DAI: 49% P < 0.001

  9. Circulation 2010 122: 1144-52

  10. 1029 pacientes en 4 paises europeos Circulation 2010 121: 635-643

  11. Y ademas • Biventricular verus right ventricular antitachycardia pacing to terminate ventricular tachyarrhythmias in patients receiving cardiac resynchronization therapy: The Advance CRT-D trial. Gasparini M, Anselme F. Clementy J et al. Am Heart J 2010: 16, 1113-23. • A randomized double-blind comparison of biventricular versus left ventriclar stimulation for cardiac resynchonization therapy: The Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failurre (B-LEFT HF) trial. Boriani G, Kraning W, Donal E y cols Am Heart J 2010: 159: 1052-58 • Identification and charasterization of super-responders afther cardiac resynchronitazation therapy. Raen P, Zaroui A, Mignot A y cols. Am J Cardiol 2010: 105; 1327-35

  12. Update 2010 Fuengirola, Málaga

More Related